When considering GBM subtypes or age groups separately, no significant survival differences for GJB2 and SCN9A were found, except for an association with high SCN9A expression and worse prognosis in mesenchymal GBMs (Fig. EV2B). This evidence concerns the gene GJB2 and glioblastoma.